Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna (MRNA) delivered earnings and revenue surprises of 39.22% and -1.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Beats Q1 Earnings Estimates

The drug manufacturer announced its first profitable first quarter.

Moderna Says Covid-19 Vaccine Is 96% Effective In Teenagers, Will File For Full FDA Approval

Moderna fell 9% in pre-market trading on Thursday after reporting first-quarter earnings that missed analyst estimates. The therapeutics company reported $1.94 billion in net revenue for the three months ending in March, thanks to strong COVID-19 vaccine sales. That compared to revenue of $8 million for the same period last year, but fell short of the $2.04 billion analysts expected.

Moderna slumps 9% as the vaccine-maker's Q1 revenue misses estimates

Moderna CEO Stephane Bancel said Thursday the company expects more variants of the coronavirus will emerge in the coming months.

Moderna CEO expects more Covid variants to emerge in coming months: 'This virus is not going away'

Moderna's (MRNA) Q1 earnings exceeded analyst expectations, while revenue missed estimates. It was the company's first profitable quarter.

Moderna Q1 2021 Earnings Report Recap

Moderna Inc (NASDAQ: MRNA) reports Q1 EPS of $2.84, a turnaround from EPS loss of $0.35 a year ago, beating the consensus estimate of $2.39. However, Q1 revenues of $1.9 billion compared to $8 million a year ago fell short of the $2.04 billion consensus.

Moderna Stock Drops As Q1 Sales Fails To Meet Expectations; Anticipates $19.2B In FY21 Product Sales

Moderna Inc. said Thursday that initial data from the study evaluating its COVID-19 vaccine in teens between the ages of 12 and 17 years old showed an efficacy rate of 96%, with no serious safety concerns. The Phase 2/3 clinical trial is testing the vaccine in 3,235 teens who have received at least one shot in the two-dose regimen and have not previously been infected with SARS-CoV-2.

Moderna says its COVID-19 vaccine has a 96% efficacy rate in teens who have received one shot

BioNTech SE

Pfizer

Moderna Inc (NASDAQ:MRNA) and Pfizer Inc. (NYSE:PFE) had a double dose of good news regarding their COVID-19 vaccines. Moderna said that its tweaked jab was successful in neutralising the South African and Brazilian variants of the virus in laboratory trials.

Coronavirus: Moderna says tweaked vaccine works against variants, two BioNTech/Pfizer doses give 95% protection

Moderna Inc. brought in $1.7 billion in sales of its COVID-19 vaccine in the first quarter of 2021, marking the company's first significant billion-dollar revenue haul this year and also the first time it's ever reported a GAAP profit. Moderna had earnings of $1.2 billion, or $2.84 per share, in the first quarter of 2021.

Moderna reports $1.7 billion in COVID-19 vaccine sales, posts first profit ever

Moderna said its Covid-19 vaccine is 96% effective in kids ages 12 to 17, according to early data released with the company's first-quarter earnings Thursday.

Moderna says early data shows Covid vaccine is 96% effective in teens

Moderna turns around negative first-quarter earnings per share as revenue surges

Moderna Inc raised its 2021 sales forecast for its COVID-19 vaccine by 4.3% to $19.2 billion on Thursday, reflecting demand from countries looking to return to normalcy through rapid inoculation.

Moderna raises 2021 sales forecast for COVID-19 vaccine to $19.2 billion

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna reports first quarter fiscal year 2021 financial results and provides business updates.

Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces new supply agreement with Switzerland for 7 million booster vaccine doses in 2022 and option for additional 7 million doses.

Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022 and Option for Additional 7 Million Doses

Kellogg

McKesson

PayPal

Zynga

Some of the stocks that may grab investor focus today are: Moderna Inc (NASDAQ: MRNA) reported the effectiveness of its COVID-19 vaccine against variants in an internal study. The company is also expected to report quarterly earnings at $2.39 per share on revenue of $2.04 billion before the opening bell.

5 Stocks To Watch For May 6, 2021

Johnson & Johnson

Novavax

AstraZeneca

If enacted, such a move would hit the smaller vaccine makers particularly hard.

Biden Administration Supports Patent Waivers for Coronavirus Vaccine

Two types of booster proved efficacious against a pair of more threatening coronavirus variants.

Moderna Reports Excellent Results From Coronavirus Vaccine Booster Trial

Moderna says COVID booster shows promising response against some variants

Moderna Inc. stock rose more than 1% in the extended session Wednesday after the biotechnology company said that a single-dose booster COVID-19 vaccine worked against the novel coronavirus' variants, according to initial data from a Phase 2 study. The booster was effective against the variant first identified in South Africa and the variant first identified in Brazil, Moderna said.

Moderna says trial booster vaccine effective against COVID-19 variants

Moderna is voicing confidence in a new version of its coronavirus vaccine, tailored to fight variants of the virus, as the biotech released new clinical trial data Wednesday testing it booster doses.  These are the first clinical results from any vaccine developer testing an updated version of a COVID-19 shot. Moderna started new research earlier this year to see if it could develop a booster shot that would better protect against the B.1.351 variant first found in South Africa.

We just got our first evidence that Moderna's coronavirus booster shot works to fight variants

Moderna said its booster dose increased neutralizing antibody responses against the original virus as well as B.1.351 and P.1 variants.

Moderna says Covid booster shot generates promising immune response against variants found in South Africa, Brazil

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces positive initial booster data against SARS-CoV-2 variants of concern.

Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern

Probably not, but the study could benefit another vaccine maker.

Should Pfizer and Moderna Be Worried About This New COVID Vaccine Study?

The biotech just provided a big clue that sales are poised to skyrocket.

Why Moderna Could Triple Its COVID Vaccine Sales Next Year

Shares of Moderna Inc. were down 0.3% in premarket trading on Tuesday after the company said it will double the size of its manufacturing space at its facility in Norwood, Mass., essentially allowing for a 50% increase in the production of its COVID-19 vaccine there.

News for Moderna Stock (MRNA)